Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo - PubMed (original) (raw)
Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo
Mei-Ling Chen et al. Proc Natl Acad Sci U S A. 2005.
Abstract
Cancer patients can harbor significant numbers of CD8 and CD4 T cells with specificities to tumor antigens (Ags). Yet, in most cases, such T cells fail to eradicate the tumor in vivo. Here, we investigated the interference of Ag-specific CD4(+)CD25(+) regulatory T cells (Treg) with the tumor-specific CD8 T cell immune response in vivo, by monitoring the homing, expansion, and effector function of both subsets in draining and nondraining lymph nodes. The results show that CD8 cells expand to the same extent and produce similar levels of IFN-gamma in the presence or absence of Ag-specific Treg. Nevertheless, these Treg abrogate CD8 T cell-mediated tumor rejection by specifically suppressing the cytotoxicity of expanded CD8 cells. The molecular mechanism of suppression involves TGF-beta because expression of a dominant-negative TGF-beta receptor by tumor-specific CD8 cells renders them resistant to suppression and is associated with tumor rejection and unimpaired cytotoxicity.
Figures
Fig. 1.
HA-specific CD8 T cells selectively reject HA-expressing tumors in the absence of HA-specific CD4 Treg. On day -1, BALB/c mice were not treated (a) or were adoptively transferred with different combinations of HA-specific T cells as follows: 105 naïve CD8 T cells (b), 105 naïve CD8 T cells and 105 CD4 Treg (c), or 105 naïve CD8 and 105 naïve CD4 T cells (d). On day 0, two colon carcinoma cell lines, namely CT26 (HA-) and CT44 (HA+), were s.c. inoculated in the right and left footpads, respectively. Tumor size was measured over a period of 2 wk. Results show mean and SD values of nine or more mice from at least three independent experiments.
Fig. 2.
HA-specific CD4 Treg neither impair proliferation nor accelerate apoptosis of HA-specific CD8 T cells. Thy1.1 BALB/c mice were adoptively transferred on day -1 with different combinations of CFSE-labeled Thy1.2 HA-specific T cells and challenged with CT26 (HA-) and CT44 (HA+) tumors on day 0 as described in Fig. 1. (a) CT44 draining LN from mice that received either naïve HA-specific CD8 T cells (○) or naïve HA-specific CD8 T cells and HA-specific CD4 Treg (•) were collected at different time points, and frequency of the transferred CD8 T cells (defined as CD8+Thy1.2+) was quantified by flow cytometry. (b) CD8 T cells in CT44 draining LN were assessed on day 6 for cell division (CFSE distribution) and apoptosis (binding to annexin V). (c) Similar analysis was performed with cells retrieved in CT26 tumor draining LN at the same time point. Similar results were obtained on days 4 and 8 (data not shown). Results show mean and SD values of six or more mice from at least three independent experiments.
Fig. 3.
HA-specific CD4 Treg do not control the production of inflammatory cytokines by HA-specific CD8 T cells. Thy1.1 BALB/c mice were adoptively transferred on day -1 with different combinations of Thy1.2 HA-specific T cells and challenged with CT44 (HA+) tumors on day 0 as described in Fig. 1, from which CT44 draining LN cells were collected on day 6. HA-specific CD8 T cells were analyzed for IFN-γ (a) and TNF-α (b) production after 4-h restimulation with exogenously added HA512-520 and HA107-119 peptides or PMA/ionomycin. (c) HA-specific CD8 T cells were analyzed for IFN-γ production after 4-h restimulation with DCs previously pulsed with only HA512-520 or both HA512-520 and HA107-119 peptides, or PMA/ionomycin. Results show mean and SD values of nine or more mice from at least three independent experiments.
Fig. 4.
HA-specific CD4 Treg suppress the cytotoxic activity of HA-specific CD8 T cells in vivo. BALB/c mice were adoptively transferred on day -1 with different combinations of HA-specific T cells and challenged with CT44 (HA+) tumors on day 0 as described in Fig. 1. Mice were injected intravenously with a 1:1 mixture of syngeneic splenocytes previously labeled with 10 μM CFSE and pulsed with HA512-520 peptide and of cells previously labeled with 1 μM CFSE but not pulsed with peptide. CT26 and CT44 draining LN were collected 16 h later, and Ag-specific killing of HA512-520 positive targets was measured by flow cytometry. (a) Representative examples for in vivo killing of HA+ targets. (b) Summary of in vivo killing of HA+ targets. n.s., not significant; *, P < 0.0001. Results show mean and SD values of nine or more mice from at least three independent experiments.
Fig. 5.
Suppression of HA-specific CD8 T cell cytotoxic activity by HA-specific CD4 Treg requires TGF-β receptor signaling. On day -1, 105 naïve HA-specific CD8 T cells expressing or not expressing dnTGFβR were adoptively transferred into BALB/c mice either alone or with 105 HA-specific CD4 Treg. Mice were challenged with CT44 (HA+) tumors on day 0. (a) HA-specific CD8 T cells in CT44 draining LN were quantified on day 6. (b) In vivo cytotoxic activity in CT44 draining LN was measured on day 6, as described in Fig. 4. n.s., not significant; *, P < 0.0001. (c) Tumor size was measured over a period of 2 wk in mice not receiving (Left) or receiving (Right) Treg. Results show mean and SD values of nine or more mice from at least three independent experiments.
Similar articles
- The suppressive effect of CD25+Treg cells on Th1 differentiation requires cell-cell contact partially via TGF-β production.
Shen E, Zhao K, Wu C, Yang B. Shen E, et al. Cell Biol Int. 2011 Jul;35(7):705-12. doi: 10.1042/CBI20100528. Cell Biol Int. 2011. PMID: 21314640 - TGF-beta1 production by CD4+ CD25+ regulatory T cells is not essential for suppression of intestinal inflammation.
Kullberg MC, Hay V, Cheever AW, Mamura M, Sher A, Letterio JJ, Shevach EM, Piccirillo CA. Kullberg MC, et al. Eur J Immunol. 2005 Oct;35(10):2886-95. doi: 10.1002/eji.200526106. Eur J Immunol. 2005. PMID: 16180248 - Mycophenolic acid-treated dendritic cells generate regulatory CD4+ T cells that suppress CD8+ T cells' allocytotoxicity.
Kazma I, Lemoine R, Herr F, Chadet S, Meley D, Velge-Roussel F, Lebranchu Y, Baron C. Kazma I, et al. Int Immunol. 2014 Mar;26(3):173-81. doi: 10.1093/intimm/dxt054. Epub 2013 Nov 12. Int Immunol. 2014. PMID: 24222014 - The impact of CD4+CD25+ Treg on tumor specific CD8+ T cell cytotoxicity and cancer.
Khazaie K, von Boehmer H. Khazaie K, et al. Semin Cancer Biol. 2006 Apr;16(2):124-36. doi: 10.1016/j.semcancer.2005.11.006. Epub 2006 Jan 26. Semin Cancer Biol. 2006. PMID: 16443370 Review. - Detection and analysis of antigen-specific CD8+ T cells.
Badovinac VP, Harty JT. Badovinac VP, et al. Immunol Res. 2001;24(3):325-32. doi: 10.1385/IR:24:3:325. Immunol Res. 2001. PMID: 11817329 Review.
Cited by
- Syngeneic Mouse Models for Pre-Clinical Evaluation of CAR T Cells.
Ahmed EN, Cutmore LC, Marshall JF. Ahmed EN, et al. Cancers (Basel). 2024 Sep 18;16(18):3186. doi: 10.3390/cancers16183186. Cancers (Basel). 2024. PMID: 39335157 Free PMC article. Review. - Tregs delivered post-myocardial infarction adopt an injury-specific phenotype promoting cardiac repair via macrophages in mice.
Alshoubaki YK, Nayer B, Lu YZ, Salimova E, Lau SN, Tan JL, Amann-Zalcenstein D, Hickey PF, Del Monte-Nieto G, Vasanthakumar A, Martino MM. Alshoubaki YK, et al. Nat Commun. 2024 Aug 1;15(1):6480. doi: 10.1038/s41467-024-50806-y. Nat Commun. 2024. PMID: 39090108 Free PMC article. - Development of human pancreatic cancer avatars as a model for dynamic immune landscape profiling and personalized therapy.
Hughes D, Evans A, Go S, Eyres M, Pan L, Mukherjee S, Soonawalla Z, Willenbrock F, O'Neill E. Hughes D, et al. Sci Adv. 2024 Jul 5;10(27):eadm9071. doi: 10.1126/sciadv.adm9071. Epub 2024 Jul 5. Sci Adv. 2024. PMID: 38968363 Free PMC article. - Exploiting ferroptosis vulnerabilities in cancer.
Nakamura T, Conrad M. Nakamura T, et al. Nat Cell Biol. 2024 Sep;26(9):1407-1419. doi: 10.1038/s41556-024-01425-8. Epub 2024 Jun 10. Nat Cell Biol. 2024. PMID: 38858502 Review. - Subcutaneous biodegradable scaffolds for restimulating the antitumour activity of pre-administered CAR-T cells.
Zhang DKY, Brockman JM, Adu-Berchie K, Liu Y, Binenbaum Y, de Lázaro I, Sobral MC, Tresa R, Mooney DJ. Zhang DKY, et al. Nat Biomed Eng. 2024 Jun 3. doi: 10.1038/s41551-024-01216-4. Online ahead of print. Nat Biomed Eng. 2024. PMID: 38831041
References
- Shevach, E. M. (2004) Semin. Immunol. 16, 69-71. - PubMed
- Sakaguchi, S. (2004) Annu. Rev. Immunol. 22, 531-562. - PubMed
- Suri-Payer, E., Amar, A. Z., Thornton, A. M. & Shevach, E. M. (1998) J. Immunol. 160, 1212-1218. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials